CEL-SCI CORPORATION Increase (Decrease) in Derivative Liabilities
CEL-SCI CORPORATION (CVM) reported Increase (Decrease) in Derivative Liabilities of $0 for the 12-month period ending 2013-09-30, per its 10-K filed 2013-12-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2013-12-27
- CEL-SCI CORPORATION increase (decrease) in derivative liabilities for the quarter ending 2013-09-30 was $0.00.
- CEL-SCI CORPORATION increase (decrease) in derivative liabilities for the quarter ending 2013-06-30 was $0.00.
- CEL-SCI CORPORATION increase (decrease) in derivative liabilities for the quarter ending 2012-09-30 was $0.00.
- CEL-SCI CORPORATION increase (decrease) in derivative liabilities for the quarter ending 2012-06-30 was $0.00.
- CEL-SCI CORPORATION increase (decrease) in derivative liabilities for fiscal 2013 was $0.00.
- CEL-SCI CORPORATION increase (decrease) in derivative liabilities for fiscal 2012 was -$122.37K.
- CEL-SCI CORPORATION increase (decrease) in derivative liabilities for fiscal 2011 was -$202.83K.
- CEL-SCI CORPORATION increase (decrease) in derivative liabilities for fiscal 2010 was -$5.51M.
| Period end | Increase (Decrease) in Derivative Liabilities 3 month | Increase (Decrease) in Derivative Liabilities 6 month | Increase (Decrease) in Derivative Liabilities 9 month | Increase (Decrease) in Derivative Liabilities 9 month as first filed | Increase (Decrease) in Derivative Liabilities 12 month | Increase (Decrease) in Derivative Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2013-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-27 | $0.00 derived: sum of 2 quarters · filed 2013-12-27 | $0.00 10-K · filed 2013-12-27 | |||
| 2013-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-09 | $0.00 10-Q · filed 2013-08-09 | ||||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-10 | |||||
| 2012-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-27 | $0.00 derived: sum of 2 quarters · filed 2013-12-27 | -$122.37K derived: sum of 3 quarters · filed 2013-12-27 | -$122.37K 10-K · filed 2013-12-27 | ||
| 2012-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-09 | -$122.37K derived: sum of 2 quarters · filed 2013-08-09 | -$122.37K 10-Q · filed 2013-08-09 | -$122.37K derived: sum of 4 quarters · filed 2013-12-27 | ||
| 2012-03-31 | -$122.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-05-10 | -$122.37K 10-Q · filed 2013-05-10 | -$122.37K derived: sum of 3 quarters · filed 2013-12-27 | -$122.37K derived: sum of 4 quarters · filed 2013-12-27 | ||
| 2011-12-31 | $0.00 10-Q · filed 2012-02-09 | $0.00 derived: sum of 2 quarters · filed 2013-12-27 | $0.00 derived: sum of 3 quarters · filed 2013-12-27 | -$141.22K derived: sum of 4 quarters · filed 2013-12-27 | ||
| 2011-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-27 | $0.00 derived: sum of 2 quarters · filed 2013-12-27 | -$141.22K derived: sum of 3 quarters · filed 2013-12-27 | -$202.83K 10-K · filed 2013-12-27 | $202.83K 10-K · filed 2011-12-23 | |
| 2011-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-08-09 | -$141.22K derived: sum of 2 quarters · filed 2012-08-09 | -$202.83K 10-Q · filed 2012-08-09 | $202.83K 10-Q · filed 2011-08-09 | -$11.22M derived: sum of 4 quarters · filed 2012-12-14 | |
| 2011-03-31 | -$141.22K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-05-10 | -$202.83K 10-Q · filed 2012-05-10 | -$11.22M derived: sum of 3 quarters · filed 2012-12-14 | |||
| 2010-12-31 | -$61.62K 10-Q · filed 2012-02-09 | -$11.08M derived: sum of 2 quarters · filed 2012-12-14 | ||||
| 2010-09-30 | -$11.02M derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-14 | -$5.51M 10-K · filed 2012-12-14 | $5.51M 10-K · filed 2011-12-23 | |||
| 2010-06-30 | $5.51M 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |